We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

I'm ok with this

Media | Grünenthal Group
;

Discover Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focussing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of € 1.3 bn.

12/10/2019

Aachen, 10 December 2019 – Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective 1 January 2020. Since July 2019, Jan has already served as acting CSO, leading the strategic re-alignment of Grünenthal’s R&D organisation.

12/3/2019

Aachen, 3. Dezember 2019 – Grünenthal und die Uniklinik RWTH Aachen geben heute bekannt, dass sie eine Forschungskooperation eingegangen sind, um neue Behandlungsansätze für Patienten mit neuropathischen Schmerzen zu entwickeln. Das Projekt Bio2Treat – Biometrische und biologische Daten für die Diagnose und Therapie bei Schmerzpatienten – läuft über drei Jahre. Es wird als Teil des Aktionsfelds „Gesundheitswirtschaft im Rahmenprogramm Gesundheitsforschung“ vom Bundesministerium für Bildung und Forschung (BMBF) mit insgesamt € 1,52 Millionen gefördert (Förderkennzeichen 13GW0334B). An dem Projekt, das Prof. Angelika Lampert aus dem Institut für Physiologie der Uniklinik RWTH Aachen zusammen mit Grünenthal koordiniert, sind die Professoren Roman Rolke (Palliativmedizin), Martin Zenke (Zellbiologie), Ingo Kurth (Humangenetik) und Andreas Schuppert (Computational Biomedicine) der Uniklinik RWTH Aachen beteiligt.

9/10/2019

Aachen, Germany, and Melbourne, Australia, 10 September 2019 – Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in allogeneic cellular medicines for inflammatory diseases, today announced that they have entered into a strategic partnership to develop and commercialise MPC-06-ID, a Phase III allogeneic cell therapy candidate for the treatment of chronic low back pain due to degenerative disc disease in patients who have exhausted conservative treatment options. Under the partnership, Grünenthal will have exclusive commercialisation rights to MPC-06-ID for Europe and Latin America.

9/6/2019

Brussels/Aachen, 6 September 2019. One in five European citizens suffers from chronic pain. For this reason, research in pain is more important than ever. During the Congress of the European Pain Federation EFIC®, four young scientists presented the results of research projects that explore creative approaches to improving the lives of patients in pain.

9/3/2019

Aachen, Germany, and Brisbane, Australia, 03 September 2019 – Grünenthal, a global leader in pain research and management, and UniQuest, The University of Queensland’s commercialisation company, today announced they have entered into a collaboration to develop novel, non-opioid drug therapies derived from the group of alpha-conotoxins as analgesic and disease modifying treatments of chronic neuropathic pain. The project’s scientific foundation was laid at The University of Queensland (UQ) by Dr. Richard Clark from the School of Biomedical Sciences in the Faculty of Medicine. The collaboration combines the expertise of UQ in target and peptide – specifically conotoxin – drug discovery and Grünenthal’s long-standing expertise in bringing innovative treatments to people living with pain worldwide.

8/13/2019

Aachen, 13. August 2019 – Die Geschäftsführung und der Betriebsrat von Grünenthal haben sich auf ein Maßnahmenpaket geeinigt, um den Forschungs- und Entwicklungsbereich des Unternehmens neu aufzustellen. Die Reorganisation umfasst einen Abbau von 191 Vollzeitstellen in der Forschung und Entwicklung und 10 Vollzeitstellen im Bereich Finance. Betriebsbedingte Kündigungen sollen möglichst vermieden werden. Das Unternehmen plant, den Personalabbau durch interne Versetzungen, Altersteilzeitlösungen und ein Freiwilligenprogramm umzusetzen. Letzteres bietet finanzielle Anreize und externe Beratungsangebote, um Mitarbeiter bei einem Stellenwechsel zu unterstützen.

6/12/2019

Madrid, Spain, 12 June 2019 – A pan-European survey initiated by Grünenthal and presented at this year’s annual European Congress of Rheumatology (EULAR 2019) in Madrid indicates that gout is being diagnosed late and is not controlled effectively or monitored regularly enough. Despite these significant gaps in the management of the disease, 8 out of 10 patients claim they are satisfied with their current treatment1.